What to make of Gilead's latest NASH deal

Gilead and Glympse Bio will test whether synthetic biomarkers can show how badly damaged patients' livers are. It's a partnership that hints at the biotech's commitment to NASH.

By Jacob Bell • Oct. 28, 2019

Pharmacquired: Eylea could be in trouble, but that doesn't make Regeneron a buyer

A rival medicine from Novartis and potential changes to Medicare aren't likely enough for Regeneron to reverse its decades-long aversion to M&A.

By Jacob Bell • Oct. 25, 2019

GSK hands 2 of its less profitable vaccines to Bavarian Nordic

The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.

By Jacob Bell • Oct. 21, 2019

Sanofi investing in gene therapy as R&D focus turns toward rare disease

R&D chief John Reed told BioPharma Dive Sanofi is retrofitting a vaccine facility in France to produce the viral vectors needed to deliver gene therapies.

By Andrew Dunn • Oct. 17, 2019

Alexion bids for a smaller version of itself, spurring concerns about the FTC

With the Roche-Spark deal in limbo, analysts are concerned that companies with overlapping pipelines may have trouble completing acquisitions.

By Jacob Bell • Oct. 16, 2019

Reata buys drug rights back from AbbVie for $330M before readout

"It shows our confidence, but we'll have to see how the data plays out," the biotech's CFO told BioPharma Dive.

By Andrew Dunn • Oct. 10, 2019

UCB bets more on rare disease drugs with Ra Pharma acquisition

The $2.5 billion deal hands UCB another late-stage drug for generalized myasthenia gravis, a disease area dominated by Alexion Pharmaceuticals.

By Jacob Bell • Oct. 10, 2019

Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird

The deal may come too late, though, as the launch of Hemlibra and approach of gene therapies dampens demand for Novo's factor replacement therapies.

By Jonathan Gardner • Oct. 9, 2019

Akcea inks deal with Pfizer, rebounding after leadership shuffle

Two weeks after a mass C-suite departure, a $250 million payment from Pfizer shored up Akcea's finances and enlivened investors in the Ionis affiliate.

By Jonathan Gardner • Oct. 7, 2019

Sobi finds another fit for its dealmaking strategy

The rare disease drugmaker plans to acquire Dova Pharmaceuticals and its blood medicine Doptelet for up to $915 million.

By Jacob Bell • Sept. 30, 2019

Clovis shares plunge after downgrade raises questions on path forward

A Wall Street analyst was skeptical of a preclinical deal that adds R&D costs while the company fights for market share in ovarian cancer.

By Jonathan Gardner • Sept. 24, 2019

Alder's migraine drug attracted plenty of dealmakers. The company, not so much

A new regulatory filing affirms the theory that, in neuroscience, risk-sharing partnerships are more appealing than all-out acquisitions.

By Jacob Bell • Sept. 24, 2019

Lundbeck buys into migraine, acquiring Alder for $2B

The Danish pharma has blockbuster ambitions for Alder's CGRP drug, but the already competitive migraine market is poised to become more so next year.

By Andrew Dunn • Sept. 16, 2019

Vertex makes headway in UK reimbursement

Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.

By Jacob Bell • Sept. 12, 2019

Reata's new CFO on M&A, weathering a recession and biotech's quirks

Manmeet Soni helped execute multi-billion dollar sales as CFO of Ariad and Pharmacyclics. He's now moving from Alnylam to a small, Texas-based biotech.

By Andrew Dunn • Sept. 12, 2019

Drug companies pay for exclusive access to UK genetic data

Amgen, AstraZeneca, GSK and J&J will get nine months to pour over the first wave of whole genome data coming out of UK Biobank before the global research community gets a chance to look.

By Jacob Bell • Sept. 11, 2019

Sanofi paying Lexicon $260M to exit diabetes alliance

Lexicon had argued Sanofi violated the companies' contract when providing notice in July that it would terminate a research partnership on Zynquista.

By Ned Pagliarulo • Sept. 11, 2019

Roivant offloads biotech stakes in $3B alliance with Japanese pharma

The deal transfers ownership in five Roivant subsidiaries to Sumitomo Dainippon, along with a stake in Vivek Ramaswamy's parent company. 

By Jonathan Gardner • Sept. 6, 2019

With third pharma deal, IFM's unorthodox approach paying off

An inflammatory disease partnership with Novartis is IFM's second this year with the Swiss pharma and follows a 2017 deal with Bristol-Myers Squibb. 

By Ned Pagliarulo • Sept. 5, 2019

Celltrion taps Lonza to produce some of its Remicade biosimilar

Under the deal, Lonza will make Remsima drug substance at its commercial facility in Singapore to cover European and North American markets.

By Jacob Bell • Sept. 5, 2019

Pharmacquired: Vertex has an appetite for deals. Gene therapy is on the menu

CEO Jeffrey Leiden told BioPharma Dive that one or two gene therapy deals wouldn't be surprising as the biotech builds out what he calls its tool kit of technologies.

By Jacob Bell • Sept. 5, 2019

Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure

Acquiring Semma Therapeutics fulfills CEO Jeffrey Leiden's promise that Vertex would explore "potentially larger" deals than it's done in the past.

By Andrew Dunn • Sept. 3, 2019

Catalent's legacy business outshined by acquisitions

The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business. 

By Jacob Bell • Aug. 29, 2019

Immatics shows Celgene isn't done stocking cell therapy pipeline

As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.

By Jonathan Gardner • Aug. 28, 2019

Zogenix buys Modis for $250M, building out rare disease pipeline

Modis Therapeutics, a private California-based biotech, is developing a drug for an ultra-rare neuromuscular disorder with no approved treatments.

By Andrew Dunn • Aug. 26, 2019